| |
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas
- 作者:Andrew D. Norden ; David Schiff ; Manmeet S. Ahluwalia…
- 关键词:High ; grade glioma ; Nintedanib ; Anti ; angiogenic therapy
- 刊名:Journal of Neuro-Oncology
- 出版年:2015
- 出版时间:January 2015
- 年:2015
- 卷:121
- 期:2
- 页码:297-302
- 全文大小:206 KB
- 参考文献:1. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-740 CrossRef
2. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-45 CrossRef 3. Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. doi:10.1093/neuonc/nou028 4. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550-55 CrossRef 5. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-5 CrossRef 6. Erber R, Thurnher A, Katsen A, Groth G, Kerger H, Hammes H, Menger M, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-40 7. Guo P, Hu B, Gu W, Xu L, Wang D, Huang H, Cavenee W, Cheng S (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162:1083-093 CrossRef 8. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774-782. doi:10.1158/0008-5472.CAN-07-6307 CrossRef 9. Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U (2013) Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol 111:205-12. doi:10.1007/s11060-012-1009-y CrossRef 10. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-972. doi:10.1200/JCO.2009.26.3541 CrossRef 11. Simon R (1987) How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079-085 12. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jurgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212-218. doi:10.1200/JCO.2012.47.2464 Andrew D. Norden (1) (2) (3) David Schiff (4) Manmeet S. Ahluwalia (5) Glenn J. Lesser (6) Lakshmi Nayak (1) (2) (3) Eudocia Q. Lee (1) (2) (3) Mikael L. Rinne (1) (2) (3) Alona Muzikansky (7) Jorg Dietrich (8) Benjamin Purow (4) Lisa M. Doherty (2) Debra C. LaFrankie (2) Julee R. Pulverenti (2) Jennifer A. Rifenburg (2) Sandra F. Ruland (2) Katrina H. Smith (2) Sarah C. Gaffey (2) Christine McCluskey (2) Keith L. Ligon (10) (3) (9) David A. Reardon (2) (3) Patrick Y. Wen (1) (2) (3)
1. Division of Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital, 75 Francis St., Boston, MA, 02115, USA 2. Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA 3. Harvard Medical School, 25 Shattuck St., Boston, MA, 02115, USA 4. University of Virginia School of Medicine, PO Box 800793, Charlottesville, VA, 22908, USA 5. Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA 6. Comprehensive Cancer Center of Wake Forest University, Medical Center Boulevard, Winston-Salem, NC, 27157, USA 7. Massachusetts General Hospital Biostatistics Center, 50 Staniford St., Boston, MA, 02114, USA 8. Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit St., Boston, MA, 02114, USA 10. Department of Pathology, Brigham and Women’s Hospital, 75 Francis St., Boston, MA, 02115, USA 9. Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA
- 刊物类别:Medicine
- 刊物主题:Medicine & Public Health
Oncology
- 出版者:Springer Netherlands
- ISSN:1573-7373
文摘
Bevacizumab is FDA-approved for patients with recurrent GBM. However, the median duration of response is only 4?months. Potential mechanisms of resistance include upregulated FGF signaling and increased PDGF-mediated pericyte coverage. Nintedanib is an oral, small-molecule tyrosine kinase inhibitor of PDGFR α/β, FGFR 1-3, and VEGFR 1-3 that may overcome resistance to anti-VEGF therapy. This was a two-stage phase II trial in adults with first or second recurrence of GBM, stratified by prior bevacizumab therapy (ClinicalTrials.gov number NCT01380782; 1199.94). The primary endpoint was PFS6 in the bevacizumab-naive arm (Arm A) and PFS3 in the post-bevacizumab arm (Arm B). Up to 10 anaplastic glioma (AG) patients were accrued to each arm in exploratory cohorts. Twenty-two patients enrolled in Arm A and 14 in Arm B. Arm A included 12 GBMs (55?%), 13 patients with one prior regimen (59?%), and median age 54?years (range 28-5). Arm B included 10 GBMs (71?%), one patient with one prior regimen (7?%), and median age 52?years (range 32-0). Median KPS overall was 90 (range 60-00). There were no responses. In Arm A (GBM only), PFS6 was 0?%, median PFS 28?days (95?% CI 27-3), and median OS 6.9?months (3.7-.1). In Arm B (GBM only), PFS3 was 0?%, median PFS 28?days (22-8), and median OS 2.6?months (1.0-.9). Among AG patients in each arm, PFS6 was 0?%. Treatment was well tolerated. In conclusion, nintedanib is not active against recurrent high-grade glioma, regardless of prior bevacizumab therapy.
| |
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.
| |